FUNDAMENTALS · Fundamentals · KR Healthcare

DIO (039840) Fundamentals 2026 — P/E 19.4x, Revenue Analysis | SniperIQ

DIO (039840) is a KR-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₩155.9B, trading at ₩12110.00 on the KOE. This SniperIQ fundamentals page covers DIO's valuation (P/E 19.4x, P/B 0.9x), profitability (net margin 4.8%), revenue (₩164.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩155.9B
P/E (TTM)19.4x
Net Margin4.8%
Revenue (FY25)₩164.1B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is DIO's market cap?

DIO (039840) has a market capitalization of approximately ₩155.9B, trading at ₩12110.00 on the KOE. Market cap moves with the live share price.

What is DIO's P/E ratio?

DIO's trailing twelve-month P/E ratio is 19.4x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is DIO?

DIO runs a net profit margin of 4.8%, a gross margin of 65.2%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does DIO generate?

DIO reported revenue of ₩164.1B for fiscal year 2025, with net income of -₩1.4B and earnings per share (EPS) of -94.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does DIO pay a dividend?

DIO does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is DIO financially healthy?

DIO carries a debt-to-equity ratio of 0.44x and a current ratio of 1.60x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is DIO a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DIO (039840) the key facts are: market cap ₩155.9B, P/E 19.4x, revenue ₩164.1B, 52-week range 11420-19400. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track DIO's full fundamentals live

Get DIO's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Jubilant Pharmova (JUBLPHARMA) fundamentals · JETEMA (216080) fundamentals · Interojo (119610) fundamentals · Bioneer (064550) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons